WO2014182261A1 - A composition for the treatment of neuroendocrinal damage caused by autoimmune diseases - Google Patents
A composition for the treatment of neuroendocrinal damage caused by autoimmune diseases Download PDFInfo
- Publication number
- WO2014182261A1 WO2014182261A1 PCT/TR2013/000323 TR2013000323W WO2014182261A1 WO 2014182261 A1 WO2014182261 A1 WO 2014182261A1 TR 2013000323 W TR2013000323 W TR 2013000323W WO 2014182261 A1 WO2014182261 A1 WO 2014182261A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- autoimmune diseases
- extract
- neuroendocrinal
- damage caused
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Definitions
- the invention relates to a composition comprising dioscin derivatives and 98-E, eurycoma longifolia and cissus extracts for treating the neuroendocrinal damage caused by the autoimmune diseases.
- Autoimmunity is the general name for the reactions that develop due to the hypersensitivity of the immune system.
- the immune system mistakenly detects the body's own constituent tissues as "intruding matter", fails to recognize these tissues and produces antibodies against them; hence the immune system cells attack the body's own constituent tissues.
- autoimmune diseases although not high in number, are of the idiopathic nature; in other words, their causes have not been fully understood.
- the corticosteroids are employed in the treatment of the autoimmune diseases as a general rule.
- SLE Systemic lupus erythematosus
- sarcoidosis idiopathic pulmonary fibrosis
- behcet's disease canine myositis eosinophilica, hypogammaglobulinemia, meniere syndrome, juvenile rheumatoid arthritis, kawasaki disease, wilson syndrome, multiple sclerosis, ankylosing spondylitis.
- the definitive treatment is not still possible for the autoimmune diseases.
- the definitive treatment may be obtained for the autoimmune diseases by the use of the stem cells.
- the studies are under way on the destruction of the T cells that detect the own cells of a body as the intruding matter and the transplantation of the blood stem cells producing the normal healthy T cells to replace' the destroyed cells.
- the blood stem cells obtained from the individual's own bone marrow may be grown in cultures and the T and B cells may be obtained from these. When administered back to the patient, these cells do -not attack the body's own cells any more.
- Another treatment method employed according to the state of the art involves the control and suppression of the genetic mechanism in the cells of the immune system.
- the cells of the immune system secrete various molecules when they are activated.
- EP1933869B1 entitled "Use of IL-23 and IL-17 antagonists for treating the autoimmune inflammatory eye disease” deals with the novel methods and drug products involving the administration of the substances, which antagonize one or both of the activity of IL-23 and IL-17 in order to treat the autoimmune inflammatory eye disease.
- the invention no. EP1951687B1 entitled "N-Hydroxyamide derivatives and the use thereof relates to the N-hydroxyamide derivatives, their pharmaceutical composition, the methods for the preparation of the same and the use thereof for the treatment and/or prophylaxis of the autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis.
- the invention relates specifically to N-hydroxyamide derivatives for the modulation, particularly the inhibition of the activity or function of the matrix metalloproteinases.
- the invention no. EP2056807B1 entitled “Treatment of the Inflammatory Diseases” relates generally to the inflammatory diseases of the peripheral nervous system. More particularly, the invention relates to the methods for treating the inflammatory diseases of the peripheral nervous system by way of the modulation of the sphingosine-1 -phosphate receptor activity. In an embodiment, the invention provides a method consisting of the administration of an effective amount of FTY720 in order to treat a subject with chronic inflammatory demyelinating polyneuropathy (CIDP) djsease or other autoimmune neuropathies.
- CIDP chronic inflammatory demyelinating polyneuropathy
- an object of the invention is to treat the neuroendocrinal damage caused by the autoimmune diseases.
- Another object of the invention is to increase the NGF expression, thereby supporting the production of new nerve cells.
- Another object of the invention is to support the axone regeneration rate and the presynaptic neurotransmission.
- Another object of the invention is to suppress IL-4, IL-6 and tnf-alpha.
- Another object of the invention is to stimulate the repair of the muscle and connective tissue.
- Another object of the invention is to promote the production of testosterone.
- the invention is a composition for treating the neuroendocrinal damage caused by the autoimmune diseases, said composition being obtained by the components selected from the group comprising dimethyldioscin, 98-e, eurycoma longifolia extract, cissus extract that are used individually or in combinations.
- the invention is a composition comprising dioscin derivatives and 98-E, eurycoma longifolia and cissus extracts for treating the neuroendocrinal damage caused by the autoimmune diseases.
- Dimethyl dioscin and 98-E ingredients of the invention, increase the NGF expression, thereby supporting the production of new nerve cells.
- Dimethyldioscin and 98-E also support the axone regeneration rate and the presynaptic neurotransmission.
- Eurycoma longifolia extract (100:1) and Cissus extract also stimulate the repair of the muscle and connective tissue.
- Eurycoma longifolia extract (100:1) and Cissus extract also promote the production of testosterone.
- composition according to the invention contains dimethyldioscin, 98-e, eurycoma longifolia extract (100:1), cissus extract (5:1), (10:1).
- Said formulation is obtained by a mixture of the aforesaid components according to the following ratios by weight:
- composition is obtained from the aforesaid components selected from the aforesaid group and used according to the mentioned weight ratio ranges individually or in combinations.
- Said invention also encompasses the use of said composition for treating the neuroendocrinal damage caused by the autoimmune diseases and the manufacture thereof for this purpose.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a composition for treating the neuroendocrinal damage caused by the autoimmune diseases.
Description
Description
A COMPOSITION FOR THE TREATMENT OF NEUROENDOCRINAL DAMAGE CAUSED BY AUTOIMMUNE DISEASES
Technical Field
The invention relates to a composition comprising dioscin derivatives and 98-E, eurycoma longifolia and cissus extracts for treating the neuroendocrinal damage caused by the autoimmune diseases.
State of the Art
Autoimmunity is the general name for the reactions that develop due to the hypersensitivity of the immune system. In the case of autoimmunity, the immune system mistakenly detects the body's own constituent tissues as "intruding matter", fails to recognize these tissues and produces antibodies against them; hence the immune system cells attack the body's own constituent tissues.
In addition, nearly all the autoimmune diseases, although not high in number, are of the idiopathic nature; in other words, their causes have not been fully understood. The corticosteroids are employed in the treatment of the autoimmune diseases as a general rule.
Some of the autoimmune diseases widely known at the present may be listed as follows: Systemic lupus erythematosus (SLE), sarcoidosis, idiopathic pulmonary fibrosis, behcet's disease, canine myositis eosinophilica, hypogammaglobulinemia, meniere syndrome, juvenile rheumatoid arthritis, kawasaki disease, wilson syndrome, multiple sclerosis, ankylosing spondylitis.
Currently, the definitive treatment is not still possible for the autoimmune diseases. There is the hope that the definitive treatment may be obtained for the autoimmune diseases by the use of the stem cells. The studies are under way on the destruction of the T cells that detect the own cells of a body as the intruding matter and the transplantation of the blood stem cells producing the normal healthy T cells to
replace' the destroyed cells. The blood stem cells obtained from the individual's own bone marrow may be grown in cultures and the T and B cells may be obtained from these. When administered back to the patient, these cells do -not attack the body's own cells any more. Another treatment method employed according to the state of the art involves the control and suppression of the genetic mechanism in the cells of the immune system. The cells of the immune system secrete various molecules when they are activated. The synthesis of these molecules is under the control of some genes. It is expected to alter the genetic structure in the stem cells to be able to take these genes under control. In this way, the secretion of the substances harming the body would be prevented. These genetically engineered stem cells, when administered back to the patient, produce normal T and B cells that do not harm the body's own cells.
The invention no. EP1933869B1 entitled "Use of IL-23 and IL-17 antagonists for treating the autoimmune inflammatory eye disease" deals with the novel methods and drug products involving the administration of the substances, which antagonize one or both of the activity of IL-23 and IL-17 in order to treat the autoimmune inflammatory eye disease.
Further, the invention no. EP1951687B1 entitled "N-Hydroxyamide derivatives and the use thereof relates to the N-hydroxyamide derivatives, their pharmaceutical composition, the methods for the preparation of the same and the use thereof for the treatment and/or prophylaxis of the autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis. The invention relates specifically to N-hydroxyamide derivatives for the modulation, particularly the inhibition of the activity or function of the matrix metalloproteinases.
Further, the invention no. EP2056807B1 entitled "Treatment of the Inflammatory Diseases" relates generally to the inflammatory diseases of the peripheral nervous system. More particularly, the invention relates to the methods for treating the inflammatory diseases of the peripheral nervous system by way of the modulation of the sphingosine-1 -phosphate receptor activity. In an embodiment, the invention provides a method consisting of the administration of an effective amount of FTY720
in order to treat a subject with chronic inflammatory demyelinating polyneuropathy (CIDP) djsease or other autoimmune neuropathies.
As result, the presence of the need for a composition for treating the neuroendocrinal damage caused by the autoimmune diseases and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant art.
Object of the Invention
In order to eliminate the disadvantages of the state of the art, an object of the invention is to treat the neuroendocrinal damage caused by the autoimmune diseases.
Another object of the invention is to increase the NGF expression, thereby supporting the production of new nerve cells.
Another object of the invention is to support the axone regeneration rate and the presynaptic neurotransmission.
Another object of the invention is to suppress IL-4, IL-6 and tnf-alpha.
Another object of the invention is to stimulate the repair of the muscle and connective tissue.
Another object of the invention is to promote the production of testosterone.
In order to achieve the aforesaid advantages, the invention is a composition for treating the neuroendocrinal damage caused by the autoimmune diseases, said composition being obtained by the components selected from the group comprising dimethyldioscin, 98-e, eurycoma longifolia extract, cissus extract that are used individually or in combinations.
The structural and characteristic features and all the advantages of the invention will become more clearly understood from the detailed description provided below and
therefore, the evaluation must be made taking this detailed description into consideration.
Detailed Description of the Invention
The invention is a composition comprising dioscin derivatives and 98-E, eurycoma longifolia and cissus extracts for treating the neuroendocrinal damage caused by the autoimmune diseases. Dimethyl dioscin and 98-E, ingredients of the invention, increase the NGF expression, thereby supporting the production of new nerve cells. Dimethyldioscin and 98-E also support the axone regeneration rate and the presynaptic neurotransmission. Eurycoma longifolia extract (100:1) and Cissus extract (5:1 , 10:1), other ingredients of the invention, suppress immunoglobulin E, IL-4, IL-6 and tnf-alpha. Eurycoma longifolia extract (100:1) and Cissus extract also stimulate the repair of the muscle and connective tissue. Eurycoma longifolia extract (100:1) and Cissus extract also promote the production of testosterone.
The composition according to the invention contains dimethyldioscin, 98-e, eurycoma longifolia extract (100:1), cissus extract (5:1), (10:1).
Said formulation is obtained by a mixture of the aforesaid components according to the following ratios by weight:
13-28% dimethyldioscin,
17-44% 98-e,
50-18% eurycoma longifolia extract (100:1),
20-10% cissus extract (5:1), (10:1).
The composition is obtained from the aforesaid components selected from the aforesaid group and used according to the mentioned weight ratio ranges individually or in combinations.
Said invention also encompasses the use of said composition for treating the neuroendocrinal damage caused by the autoimmune diseases and the manufacture thereof for this purpose.
Claims
1. A composition for treating the neuroendocrinal damage caused by the autoimmune diseases, said composition being obtained by the components selected from the group comprising dimethyldioscin, 98-e, eurycoma longifolia extract, cissus extract that are used individually or in combinations.
2. A composition according to Claim 1 characterized in that it comprises 13-28% by weight dimethyldioscin.
3. A composition according to Claim 1 characterized in that it comprises 17-44% by weight 98-e.
4. A composition according to Claim 1 characterized in that it comprises 50-18% by weight eurycoma longifolia extract ( 00:1).
5. A composition according to Claim 1 characterized in that it comprises 20-10% by weight cissus extract (5:1).
6. A composition according to Claim 1 characterized in that it comprises 20-10% by weight cissus extract (10:1).
7. Use of the components according to Claims 1 to 6 obtained individually or in combinations from the group consisting of dimethyldioscin, 98-e, eurycoma longifolia extract, cissus extract for the manufacture of a composition for treating the neuroendocrinal damage caused by the autoimmune diseases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR201305319 | 2013-05-06 | ||
| TR2013/05319 | 2013-05-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2014182261A1 true WO2014182261A1 (en) | 2014-11-13 |
Family
ID=49759515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2013/000323 WO2014182261A1 (en) | 2013-05-06 | 2013-10-14 | A composition for the treatment of neuroendocrinal damage caused by autoimmune diseases |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2014182261A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002085394A1 (en) * | 2001-04-24 | 2002-10-31 | Bakulesh Mafatlal Khamar | The process of preparing the topical anti-inflammatory/analgesic preparation |
| WO2010140170A1 (en) * | 2009-06-05 | 2010-12-09 | Sunev Pharma Solution Limited | Topical micro-emulsions for the treatment of rheumatic disorders |
| TR201110106A2 (en) * | 2011-10-11 | 2012-09-21 | Can Alkoçlar Erdal | Stopping progress in autoimmune diseases is a composition that suppresses disease symptoms and promotes healing. |
-
2013
- 2013-10-14 WO PCT/TR2013/000323 patent/WO2014182261A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002085394A1 (en) * | 2001-04-24 | 2002-10-31 | Bakulesh Mafatlal Khamar | The process of preparing the topical anti-inflammatory/analgesic preparation |
| WO2010140170A1 (en) * | 2009-06-05 | 2010-12-09 | Sunev Pharma Solution Limited | Topical micro-emulsions for the treatment of rheumatic disorders |
| TR201110106A2 (en) * | 2011-10-11 | 2012-09-21 | Can Alkoçlar Erdal | Stopping progress in autoimmune diseases is a composition that suppresses disease symptoms and promotes healing. |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Auvin et al. | Inflammation induced by LPS enhances epileptogenesis in immature rat and may be partially reversed by IL1RA | |
| PH12018500162A1 (en) | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same | |
| PH12018500253A1 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| Neis et al. | Depressive-like behavior induced by tumor necrosis factor-α is abolished by agmatine administration | |
| MY197262A (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| NZ736432A (en) | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| IL294463A (en) | Methods for treating or preventing ophthalmological conditions | |
| JP2015517488A5 (en) | ||
| Duffy et al. | Managing neuropathic pain in multiple sclerosis: pharmacological interventions | |
| Yang et al. | Role of nitric oxide synthase in the development of bone cancer pain and effect of L‑NMMA | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| JP2018509393A5 (en) | ||
| Huang et al. | The anti‐spasticity drug baclofen alleviates collagen‐induced arthritis and regulates dendritic cells | |
| JP2016512247A5 (en) | ||
| CN109350616B (en) | Application of I-BRD9 or derivatives thereof in preparation of antiepileptic drugs | |
| JP2017531006A (en) | Levosimendan for use in the treatment of motor neuron disease (eg ALS) | |
| WO2014182261A1 (en) | A composition for the treatment of neuroendocrinal damage caused by autoimmune diseases | |
| JP5572845B2 (en) | Composition for inhibiting activation of glial cells | |
| Artifon et al. | Aerobic training previous to nerve compression: morphometry analysis of muscle in rats | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| EP2851074B1 (en) | Analgesic pharmaceutical composition | |
| RU2549461C2 (en) | Method and medication for treating arthritis and arthrosis | |
| US11052099B2 (en) | Use of cimicifugae rhizoma triterpenoid saponin extract, actein, and deoxyactein | |
| Kamiya et al. | CDK5, CRMP2 and NR2B in spinal dorsal horn and dorsal root ganglion have different role in pain signaling between neuropathic pain model and inflammatory pain model: 14AP4-5 | |
| JP6912072B2 (en) | Pharmaceuticals for the prevention or treatment of frontotemporal dementia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13803301 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 05/02/2016) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 13803301 Country of ref document: EP Kind code of ref document: A1 |